Current multidisciplinary management of brain metastases
Michael J. Moravan(Duke Medical Center), John P. Kirkpatrick(Duke University), Peter E. Fecci(University of Colorado Anschutz Medical Campus), Jordan A. Torok(Duke Medical Center), John H. Sampson(Duke University), Paul W. Sperduto(Methodist Hospital), Joseph K. Salama(University of California San Diego), Jeffrey Clarke(Duke Medical Center), Justus Adamson(Duke Medical Center), Scott Floyd(Duke University), April K.S. Salama(Duke University), Carey K. Anders(Duke University)
Cited by 130
Related Papers
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k